The presentation will focus primarily on the company's lead program, bardoxolone methyl, a first-in-class Antioxidant Inflammation Modulator (AIM). This agent is in pivotal studies in patients with chronic kidney disease and type 2 diabetes. Mr. Wilson will present the results of the company's successfully completed Phase 2 studies, in which the drug produced significant improvements in the glomerular filtration rate and several other measures of kidney function. Progressive decline in kidney function results in end-stage renal disease, which requires dialysis or a kidney transplant. Mr. Wilson will also discuss Reata’s development plans for the molecule, along with the company's commercial strategy and corporate goals.

CKD is a progressive loss of kidney function over a period of months or years, which can be caused by a number of conditions, including diabetes and high blood pressure. As kidney disease gets worse, waste products can build to high levels in the blood and patients may develop complications like high blood pressure, anemia (low blood count), weak bones, poor nutritional health and nerve damage. CKD also increases the risk of having heart and blood vessel disease. As kidney disease progresses, it eventually leads to kidney failure, requiring dialysis or a kidney transplant.

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. Reata is the leader in discovering and developing novel anti-inflammatory drugs targeting Nrf2, which controls the body's production of antioxidant and detoxification enzymes and has been shown to protect against a broad range of diseases associated with inflammation and oxidative stress. Reata is developing a portfolio of AIMs for a variety of inflammation-related diseases. The company's most advanced program is in late-stage clinical development for the treatment of CKD, a progressive condition affecting more than 26 million Americans. For more information, visit www.reatapharma.com.